Overview
Postoperative pain after craniotomy is often underappreciated and historically undertreated — partly due to historical concerns that opioids might mask neurological deterioration. Most pain (estimated 86% of cases) is somatic in origin — arising from the scalp incision, pericranial muscle dissection, and periosteal/bone manipulation — rather than from the brain itself, which has no nociceptors. This distinction is clinically useful: it means regional techniques targeting the scalp and soft tissues are highly relevant and effective for this procedure.
PROSPECT 2023 summary (Mestdagh et al.): The analgesic regimen for craniotomy should include paracetamol, NSAIDs, IV dexmedetomidine infusion, and a regional technique (either incision-site infiltration or scalp nerve block), with opioids reserved as rescue analgesics. This combination reflects strong evidence for a genuinely opioid-sparing, multimodal approach in a population where excessive sedation/respiratory depression carries particular neurological monitoring implications.
Pain & Intracranial Pressure — Why Analgesia Matters Beyond Comfort
Uncontrolled postoperative pain has direct neurophysiological consequences. Pain causes catecholamine release and increased cerebral oxygen consumption, contributing to cerebral hyperaemia and elevated intracranial pressure (ICP) — a particular concern in patients with reduced intracranial compliance after craniotomy. This makes effective analgesia a neuroprotective intervention, not simply a comfort measure.
This same physiology explains the historical reluctance to use opioids in this population — concern that sedation and respiratory depression (with resultant hypercapnia and further ICP elevation) could both mask neurological assessment and independently worsen ICP. The modern multimodal approach (regional block + non-opioid systemic agents + dexmedetomidine) directly addresses this tension: it provides effective analgesia while minimising the opioid burden that historically created this clinical dilemma.
Analgesic Pathway
- Paracetamol 1g PO/IV
- NSAID (if no contraindication, surgeon agreement re: bleeding risk)
- Scalp block — may be performed pre-incision
- Scalp block or incision-site infiltration
- Dexmedetomidine infusion — throughout case
- Paracetamol 1g IV (if not given pre-op)
- Pin-site block for head fixation (if applicable) — scalp block covers this
- Routine high-dose opioid infusion — avoid; minimise to support neurological assessment
- Paracetamol 1g QDS regular — scheduled IV improves satisfaction (RCT evidence)
- NSAID regular if appropriate
- Opioid PRN rescue — titrate carefully, balance analgesia with neuro-observation needs
- Regular neurological observations
✓ Recommended | ◎ Optional/conditional | ✗ Avoid/minimise. Based on PROSPECT 2023.
Systemic Analgesia
Paracetamol and NSAIDs form the basic foundation, as in most procedures — but scheduled (regular) IV paracetamol specifically improved patient satisfaction with pain management in a dedicated RCT for this procedure, supporting a proactive rather than reactive dosing approach.
| Agent | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Paracetamol | 1 g | IV/PO | QDS, scheduled | Scheduled dosing improved satisfaction in dedicated RCT (Artime et al.) |
| NSAID (e.g. ibuprofen) | 400 mg | PO/IV | TDS | Discuss bleeding risk with neurosurgical team, particularly intraoperative timing |
| Oxycodone/Morphine | Titrated, minimal | PO/IV PRN | PRN | Rescue only; lowest dose preserving neurological assessment capacity |
Scalp Block / Incision-Site Infiltration
Scalp nerve block and simple incision-site infiltration both have strong supporting evidence and are considered acceptable alternatives. Meta-analysis confirms scalp block reduces pain intensity scores, extends time to first rescue analgesia, and reduces analgesic consumption in the first 12 hours — with no significant difference between pre-incision and post-incision timing.
Anatomy
The scalp block targets six paired sensory nerves supplying the scalp: supraorbital and supratrochlear (anterior, V1 branch), auriculotemporal (lateral, V3 branch), zygomaticotemporal (lateral, V2 branch), and greater and lesser occipital nerves (posterior, cervical plexus C2). Complete coverage requires blocking all six bilaterally, or selectively targeting those near the planned incision/craniotomy site.
Technique Summary
-
Identify landmarks
Supraorbital/supratrochlear: at the supraorbital notch/medial brow. Zygomaticotemporal: along the lateral orbital rim, posterior to the lateral canthus. Auriculotemporal: 1–1.5 cm anterior to the tragus, superior to the zygomatic arch. Greater occipital: midpoint between the mastoid process and external occipital protuberance. Lesser occipital: lateral to the greater occipital, along the superior nuchal line.
-
Infiltrate each target
2–3 mL of local anaesthetic injected subcutaneously at each nerve location, fanning slightly to ensure coverage. Can be performed using landmark technique alone (no ultrasound required for most scalp nerve targets given their reliable surface anatomy).
-
Selective vs complete block
For localised craniotomies, block only the nerves overlying the planned incision/pin sites. For larger or bilateral procedures, complete bilateral six-nerve block provides more comprehensive coverage.
Dosing
| Agent | Concentration | Volume per nerve | Total volume (6 nerves, bilateral) | Duration |
|---|---|---|---|---|
| Ropivacaine | 0.5–0.75% | 2–3 mL | 24–36 mL | 8–14 h |
| Bupivacaine | 0.25–0.5% | 2–3 mL | 24–36 mL | 10–16 h |
⚠ Calculate total dose carefully — full bilateral 6-nerve block uses a relatively large cumulative volume even at modest per-site amounts. For ropivacaine 0.75%, 30 mL = 225 mg — verify against patient weight (max 3 mg/kg).
Dexamethasone or dexmedetomidine as infiltration adjuvant — added to the local anaesthetic for scalp block — showed only limited procedure-specific evidence in the PROSPECT review, so is not formally recommended despite plausible mechanism. Systemic IV dexmedetomidine (discussed below) has a stronger evidence base than the perineural/infiltration route for this procedure.
IV Dexmedetomidine Infusion
IV dexmedetomidine infusion is a specific and notable PROSPECT recommendation for craniotomy — reflecting its dual benefit of opioid-sparing analgesia and the haemodynamic stability valuable in neurosurgical anaesthesia (attenuating the pressor response to noxious stimuli such as pin placement and extubation, which can transiently elevate ICP).
| Phase | Dose | Notes |
|---|---|---|
| Loading (optional) | 0.5–1 mcg/kg over 10 min | Give slowly — bradycardia/hypotension risk if rapid |
| Maintenance infusion | 0.2–0.7 mcg/kg/h | Throughout the procedure; titrate to haemodynamic response and sedation depth requirements |
Careful titration is essential given the risk of hypotension/bradycardia and excess sedation — both particularly undesirable in a population where maintaining stable cerebral perfusion pressure and being able to perform timely neurological assessment are priorities.
Not Recommended / No Evidence
Flupirtine, intraoperative magnesium sulfate infusion, intraoperative lidocaine infusion, and infiltration adjuvants (hyaluronidase, dexamethasone, α-adrenergic agonists added to LA) all showed limited procedure-specific evidence — not formally recommended despite plausible benefit.
No supporting procedure-specific evidence was identified for these interventions in the PROSPECT systematic review.
A global practice survey found scalp block usage varies dramatically by setting (15% in high-income countries vs 43% in lower/middle-income countries), and remifentanil infusion availability differs substantially by resource setting — highlighting that recommended best practice is not uniformly accessible, and clinicians should adapt evidence-based principles to locally available resources.
Practical Analgesic Protocol
Suggested protocol for elective supratentorial craniotomy:
References
- Mestdagh FP, Lavand'homme PM, Pirard G, Joshi GP, Sauter AR, Van de Velde M; PROSPECT Working Group. Pain management after elective craniotomy: a systematic review with PROSPECT recommendations. Eur J Anaesthesiol. 2023;40:747–757. PMID 37417808 ↗
- ESRA. New PROSPECT recommendations about postoperative pain management — median sternotomy and elective craniotomy. esraeurope.org ↗
- Scalp block for postoperative pain after craniotomy: A meta-analysis of randomized control trials. PMC. PMC9550001 ↗
- Artime CA, Aijazi H, Zhang H, et al. Scheduled intravenous acetaminophen improves patient satisfaction with postcraniotomy pain management: a prospective, randomized, placebo-controlled, double-blind study. J Neurosurg Anesthesiol. 2018;30:231–236.
- Duda T, Lannon M, Gandhi P, et al. Systematic Review and Meta-Analysis of RCTs for Scalp Block in Craniotomy. Neurosurgery. 2023;93(1):4–23.
- Acute postoperative pain management in patients scheduled for craniotomy. Medigraphic. 2024. Link ↗